Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
Takumi KishimotoNobukazu FujimotoTakeshi EbaraToyonori OmoriTetsuya OguriAkio NiimiTakako YokoyamaMunehiro KatoIkuji UsamiMasayuki NishioKosho YoshikawaTakeshi TokuyamaMouka TamuraYoshifumi YokoyamaKen TsuboiYoichi MatsuoJiegou XuSatoru TakahashiMohamed AbdelgiedWilliam T AlexanderDavid B AlexanderHiroyuki TsudaPublished in: BMC cancer (2019)
Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.
Keyphrases
- end stage renal disease
- clinical trial
- induced apoptosis
- dendritic cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver fibrosis
- prognostic factors
- peritoneal dialysis
- bone marrow
- acute myeloid leukemia
- regulatory t cells
- oxidative stress
- patient reported outcomes
- cell proliferation
- open label
- study protocol